You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

482 Results
Document
Jan 2019
Drug
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Drug
Other Name(s): Tafinlar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2025
Regimen
Cancer Type:
Sarcoma, 
Soft Tissue, 
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - As monotherapy for the treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, based on criteria
Exceptional Access Program
    trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
daBRAFenib (Unfunded),
trametinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Skin, 
Melanoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
Exceptional Access Program
    daBRAfenib - For the adjuvant treatment of resected Stage III cutaneous melanoma, based on criteria
Exceptional Access Program
    trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daBRAFenib,
trametinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Document
New
Jun 2025
Document
New
Jun 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
durvalumab (Compassionate)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Updated
Jun 2025

Pages